Status:

COMPLETED

Multi Centre Study on TESS V2 Shoulder System

Lead Sponsor:

Zimmer Biomet

Conditions:

Osteoarthritis Shoulder

Fracture

Eligibility:

All Genders

18+ years

Brief Summary

This study is a Post Market Clinical Follow-up study to fulfill the post market surveillance requirements. The data collected from this study will serve the purpose of confirming safety and performanc...

Detailed Description

The objective of this retrospective and prospective, multicenter, non-controlled Post Market Clinical Follow-up study is to evaluate the mid-term (5-year) clinical performance of the TESS Version 2 An...

Eligibility Criteria

Inclusion

  • Except in special cases, the "anatomic" type is indicated for:
  • Centered osteoarthritis of the shoulder
  • Humeral head fractures
  • Rheumatoid arthritis (with intact rotator cuff)
  • Avascular necrosis of the humeral head
  • Except in special cases, the "reversed" type is indicated for:
  • Offset osteoarthritis of the shoulder
  • Massive and non-repairable rotator cuff tears
  • Rheumatoid arthritis (with degenerative rotator cuff)
  • Revision in cases of:
  • Replacement of an "anatomic" prosthesis with a "reversed" prosthesis
  • Conversion of a hemi-arthroplasty into a total arthroplasty
  • Increasing the size of the stem (length and/or diameter)
  • Replacing a glenoid prosthesis
  • Replacing a competitor's prosthesis
  • In rare cases, removing a "reversed" prosthesis and replacing it with an "anatomic" prosthesis
  • Additional inclusion criteria include
  • Patient who read, understood study information and gave informed consent (oral or written depending on specific local regulatory requirements)
  • Willing to return for follow-up evaluations

Exclusion

  • Local or systemic infections.
  • Severe muscular, neurological, or vascular deficiency of the affected joint.
  • Bone destruction or poor bone quality liable to affect the stability of the implant (Paget's disease, osteoporosis, etc.)
  • Cases where the corolla cannot be two-thirds covered with bone stock and including the stem/corolla junction.
  • Any concomitant complaint likely to affect the functioning of the implant.
  • Allergy to any of the implant components.
  • Local bone tumors.
  • Patient over 18 under law supervision

Key Trial Info

Start Date :

October 20 2010

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 31 2019

Estimated Enrollment :

106 Patients enrolled

Trial Details

Trial ID

NCT03431857

Start Date

October 20 2010

End Date

December 31 2019

Last Update

October 19 2021

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Orthokliniek Waasland

Sint-Niklaas, Belgium, 9100

2

Institut Calot

Berck, France, 59